Trials / Completed
CompletedNCT02447302
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients With Moderately to Severely Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- Arena Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etrasimod | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-10-15
- Primary completion
- 2018-02-14
- Completion
- 2018-02-14
- First posted
- 2015-05-18
- Last updated
- 2021-04-05
- Results posted
- 2021-04-05
Locations
134 sites across 21 countries: United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Latvia, Lithuania, New Zealand, Poland, Romania, Russia, South Korea, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02447302. Inclusion in this directory is not an endorsement.